A Review on Novel Target of TGF-Β/Smads and EPO in Renal Disease.

Abstract

The purpose of this article to review the role transforming growth factor (TGF-β) signaling that can manifest chronic kidney disease (CKD). It is a vital public health complication in all countries, because of both the number of people affected and the high cost of care when anticipation strategies are not effectively implemented. Public health strategies to prevent diabetes, hypertension, and obesity as risk factors for CKD are important. In recent years, accumulating evidence has indicated that genetic factors, particularly transforming growth factor (TGF-β) signaling, play a key role in the development of CKD, several mutated genes have been identified from patients with CKD, many of these mutated genes belong to members of the TGF-β signaling family. However, the role of TGF-β signaling in CKD is controversial. Transforming growth factor-β (TGF-β) regulates a variety of cellular functions in different cell types. This concise review will begin with a synopsis of the colorful history of TGF-β signaling in CKD, then covers in more detail the contemporary understanding of Epo’s physiology as well as its structure and interaction with its receptor. A major part of this article focuses on the regulation of the TGF-β signaling, SMAD protein & Epo gene, a transcription factor that plays a cardinal role in molecular adaptation to renal disorder. In the concluding section, a synopsis of Epo’s role in disorders of kidney will be followed assessment of the remarkable impact of Epo therapy in the treatment of CKD, as well as concerns that provide a strong impetus for the development of even safer and more effective treatment. TGF-β has been shown to modulate cell growth, extracellular matrix production and cell death via apoptosis, and inflammation. Advance research during recent years have been identified as the SMAD family of proteins is the key components in intracellular signaling of the TGF-β family. in this review we find out the complication associated with the novel targets regulating the signaling pathway of the transforming growth factor (TGF-β) along with the involvement of the SMAD proteins.